Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NWW9
UPID:
PLAT2_HUMAN
Alternative names:
HRAS-like suppressor 2
Alternative UPACC:
Q9NWW9; B9A7L8
Background:
Phospholipase A and acyltransferase 2, also known as HRAS-like suppressor 2, is a multifunctional enzyme exhibiting phospholipase A1/2 and acyltransferase activities. It plays a crucial role in the metabolism of glycerophospholipids, catalyzing the release of fatty acids and the transfer of acyl groups, thereby influencing the composition of cellular membranes and the production of signaling molecules.
Therapeutic significance:
Understanding the role of Phospholipase A and acyltransferase 2 could open doors to potential therapeutic strategies.